Malta CEN,
Borges MMF, Carlos ACAM, Crispim AA, Barbosa JV, Araújo ABSM, Silva LFG, de
Moura JFB, Silva PGB. Risk factors for dyseugia during chemotherapy in breast
cancer women: A cohort STROBE-guided. J Clin Exp Dent. 2026;18(2):e149-63.
doi:10.4317/jced.62680
https://doi.org/10.4317/jced.62680
___
References
|
1.
Trayes KP, Cokenakes SEH. Breast Cancer Treatment. Am Fam Physician.
2021;104(2):171-178. |
|
|
|
|
|
2.
Amorim G, Cordeiro J, Figueiredo E, Monteiro M, Ferreira A. Tratado de
oncologia. Rio de Janeiro: Revinter; 2013. p.1259-1362. |
|
|
|
|
|
3.
Werner TL, Ray A, Lamb JG, Brocklin VM, Hueftle K, Cohen AL, et al. A Phase I
Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxrubicin, and
Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clin Breast
Cancer. 2017;17(7):503-509. |
|
|
|
|
|
4.
Ongnok B, Chattipakorn N, Chattipakon SC. Doxorubicin and cisplatin induced
cognitive impairment: The possible mechanisms and interventions. Exp Neurol.
2020;32(4):113-118. |
|
|
|
|
|
5.
Costa MADL, Chagas SRP. Neoadjuvant Chemotherapy in Operable Breast Cancer:
Literature Review. Rev Bras Cancerol. 2016;59(2):261-269. |
|
|
|
|
|
6.
Eisenbran J, Scheer R, Kröz M, Schad F, Huber R. Quality of life in breast
patients during chemotherapy and concurrent therapy with a mistletoe extract.
Phytomedicine. 2016;18(1):151-157. |
|
|
|
|
|
7.
Gadisa DA, Assefa M, Wang SH. Toxicity profile of Doxrubicin-Cyclophosphamide
and Doxrubicin-Cyclophosphamide followed by Paclitaxel regimen and its
associated factors among women with breast cancer in Ethiopia: A prospective
cohort study. J Oncol Pharm Pract. 2020;26(8):1912-1920. |
|
|
|
|
|
8.
Malta CEN, Carlos ACAM, de Alencar MCM, Alves e Silva EF, Nogueira VBC, Alves
APNN, et al. Photobiomodulation therapy prevents dysgeusia chemotherapy
induced in breast cancer women treated with doxorubicin plus
cyclophosphamide: a triple-blinded, randomized, placebo-controlled clinical
trial. Support Care Cancer. 2022;30(3):2569-2580.. |
|
|
|
|
|
9.
Malta CEN, de Lima Martins JO, Carlos ACAM, Freitas MO, Magalhães IA, de
Vasconcelos HCA, et al. Risk factors for dysgeusia during chemotherapy for
solid tumors: a retrospective cross-sectional study. Support Care Cancer.
2022;30(1):313-325. |
|
|
|
|
|
10.
Ponticelli E, Clari M, Frigerio S, De Clemente A, Bergese I, Scavino E, et
al. Dysgeusia and health-related quality of life of cancer patients receiving
chemotherapy: A cross-sectional study. Eur J Cancer Care. 2017;26(2). |
|
|
|
|
|
11.
Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB. A systematic review of
dysgeusia induced by cancer therapies. Support Care Cancer.
2010;18(8):1081-1087. |
|
|
|
|
|
12.
ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2015;5(1):67-77. |
|
|
|
|
|
13.
Gampe EM, Zabernigg A, Wintner LM, Giesinger JM. Coming to your senses:
detecting taste and smell alterations in chemotherapy patients. A systematic
review. J Pain Symptom Manage. 2012;44(6):880-895. |
|
|
|
|
|
14.
Hannum ME, Koch RJ, Ramirez VA, Marks SS, Toskala AK, Herriman RD, et al.
Taste loss as a distinct symptom of COVID-19: a systematic review and
meta-analysis. Chem Senses. 2022;47:bjac001. |
|
|
|
|
|
15.
Navazesh M. Methods for collecting saliva. Ann NY Acad Sci. 1993;69(4):72-77. |
|
|
|
|
|
16.
Epstein JB, Barasch A. Taste disorders in cancer patients: pathogenesis and
approach to evaluation and treatment. Oral Oncol. 2010;46(2):77-81.. |
|
|
|
|
|
17.
Karnofsky DA. The clinical evaluation of chemotherapeutic agents in cancer.
In: Evaluation of chemotherapeutic agents. 1949:191-205. |
|
|
|
|
|
18.
Silveira MF, Marôco JP, Freire RS, Martins AMEBL, Marcopito LF. Impact of
oral health on the physical and psychosocial dimensions: an analysis using
structural equation modeling. Cad Saúde Pública. 2014;30(6):1169-1182. |
|
|
|
|
|
19.
Early Breast Cancer Trialists' Collaborative Group. Anthracycline-containing
and taxane-containing chemotherapy for early-stage operable breast cancer: a
patient-level meta-analysis of 100,000 women from 86 randomised trials.
Lancet. 2023;40(10384):1277-1292. |
|
|
|
|
|
20.
Khalaf H, Mohammed A, Shukur S, Alhalabi N, Almothafar B, Hassan M, et al.
Breast cancer: age incidence, hormone receptor status and family history in
Najaf, Iraq. J Med Life. 2022;15(10):1318-1321. |
|
|
|
|
|
21.
Chen T, Kharazmi E, Fallah M. Race and Ethnicity-Adjusted Age Recommendation
for Initiating Breast Cancer Screening. JAMA Netw Open. 2023;6(4):e238893. |
|
|
|
|
|
22.
Zaheed M, Wilcken N, Willson ML, O'Connell DL, Goodwin A. Sequencing of
anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early
breast cancer. Cochrane Database Syst Rev. 2019;2(2):CD012873. |
|
|
|
|
|
23.
Bhardwaj PV, Wang Y, Brunk E, Spanheimer PM, Abdou YG. Advances in the
Management of Early-Stage Triple-Negative Breast Cancer. Int J Mol Sci.
2023;24(15):12478.. |
|
|
|
|
|
24.
Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi
MF, et al. Towards personalized treatment for early stage ERBB2-positive
breast cancer. Nat Rev Clin Oncol. 2020;17(4):233-250. |
|
|
|
|
|
25.
Rakha EA, Tse GM, Quinn CM. An update on the pathological classification of
breast cancer. Histopathology. 2023;82(1):5-16. |
|
|
|
|
|
26.
Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers
in breast cancer. Clin Exp Med. 2023;23(1):1-16. |
|
|
|
|
|
27.
Godinho-Mota JC, Vaz-Gonçalves L, Custódio ID, Schroeder de Souza J, Mota JF,
Gonzalez MC, et al. Impact of Chemotherapy Regimens on Body Composition of
Breast Cancer Women: A Multicenter Study across Four Brazilian Regions.
Nutrients. 2023;15(7):1689. |
|
|
|
|
|
28.
van den Berg MMGA, Winkels RM, de Kruif JThCM, van Laarhoven HWM, Visser M,
de Vries JHM, et al. Weight change during chemotherapy in breast cancer
patients: a meta-analysis. BMC Cancer. 2017;17(1):259. |
|
|
|
|
|
29.
de Kruif JThCM, Visser M, van den Berg MMGA, Derks MJM, de Boer MR, van
Laarhoven HWM, et al. A longitudinal mixed methods study on changes in body
weight, body composition, and lifestyle in breast cancer patients during
chemotherapy and in a comparison group of women without cancer: study
protocol. BMC Cancer. 2019;19(1):7. |
|
|
|
|
|
30.
Buch-Larsen K, Lund-Jacobsen T, Andersson M, Schwarz P. Weight Change in
Post-Menopausal Women with Breast Cancer during Chemotherapy-Perspectives on
Nutrition, Activity and Bone Metabolism: An Interim Analysis of a 5-Year
Prospective Cohort. Nutrients. 2021;13(8):2902. |
|
|
|
|
|
31.
Khan S, Dhadda A, Fyfe D, Sundar S. Impact of neutropenia on delivering
planned chemotherapy for solid tumours. Eur J Cancer Care. 2008;17(1):19-25. |
|
|
|
|
|
32.
Lomma C, Chih H, Chan A. Adjuvant Dose Dense Chemotherapy in Patients With
Obesity: Short-Term Toxicities and Breast Cancer Outcome. Clin Breast Cancer.
2023;23(5):491-499. |
|
|
|
|
|
33.
Jalali A, Miresse D, Fahey MR, Ni Mhaonaigh N, McGuire A, Bourke E, et al.
Peripheral Blood Cell Ratios as Prognostic Indicators in a Neoadjuvant
Chemotherapy-Treated Breast Cancer Cohort. Curr Oncol. 2022;29(10):7512-7523. |
|
|
|
|
|
34.
Jimbo H, Horimoto Y, Ishizuka Y, Nogami N, Shikanai A, Saito M, et al.
Absolute lymphocyte count decreases with disease progression and is a
potential prognostic marker for metastatic breast cancer. Breast Cancer Res
Treat. 2022;196(2):291-298. |
|
|
|
|
|
35.
Truffi M, Sottotetti F, Gafni N, Albasini S, Piccotti F, Morasso C, et al.
Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer
Patients Treated with Neoadjuvant Chemotherapy. Cancers. 2022;14(21):5287. |
|
|
|
|
|
36.
da Costa R, Passos GF, Quintão NLM, Fernandes ES, Maia JRLCB, Campos MM, et
al. Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.
Br J Pharmacol. 2020;177(14):3127-3146. |
|
|
|
|
|
37.
Kim YJ. Xerostomia and Its Cellular Targets. Int J Mol Sci. 2023;24(6):5358. |
|
|
|
|
|
38.
Helei N, Kostenko E, Rusyn A, Helei V. Dental status features in patients
during anti-cancer chemotherapy (Transcarpathian Antitumor Center
experience). Georgian Med News. 2020;1(309):32-37. |
|
|
|
|
|
39.
de Sousa Né YG, Frazão DR, Bittencourt LO, Fagundes NC, Marañón-Vásquez G,
Crespo-Lopez ME, et al. Are Dental Caries Associated with Oxidative Stress in
Saliva in Children and Adolescents? A Systematic Review. Metabolites.
2022;12(9):858. |
|
|
|
|
|
40.
Pugnaloni S, Vignini A, Borroni F, Sabbatinelli J, Alia S, Fabri M, et al.
Modifications of taste sensitivity in cancer patients: a method for the
evaluations of dysgeusia. Support Care Cancer. 2020;28(3):1173-1181. |
|
|
|
|
|
41.
Boltong A, Keast R. Chemosensory science in the context of cancer treatment:
implications for patient care. Chemosens Percept. 2015;8(3):117-125. |
|
|
|
|
|
42.
Choi JH, Kim MJ, Kho HS. Oral health-related quality of life and associated
factors in patients with burning mouth syndrome. J Oral Rehabil.
2021;48(2):150-159. |
|
|
|
|
|
43.
Yoshimoto N, Inagaki M, Sekiguchi Y, Tomishima Y, Masuko K. Chemotherapy
alters subjective senses of taste and smell but not dietary patterns in
Japanese lung cancer patients. Support Care Cancer. 2020;28(4):1667-1674. |
|
|
|
|
|
44.
Corremans M, Mortelmans D, Geurden B, Luyten S, Bekkering G. Prevalence and
incidence of chemotherapy-induced taste alterations in adult cancer patients:
a systematic review protocol. JBI Evid Synth. 2022;20(5):1338-1343. |
|
|
|
|
|
45.
Imai H, Soeda H, Komine K, Otsuka K, Shibata H. Preliminary estimation of the
prevalence of chemotherapy-induced dysgeusia in Japanese patients with
cancer. BMC Palliat Care. 2013;12(1):38. |
|
|
|
|
|
46.
Denda Y, Niikura N, Satoh-Kuriwada S, Yokoyama K, Terao M, Morioka T, et al.
Taste alterations in patients with breast cancer following chemotherapy: a
cohort study. Breast Cancer. 2020;27(5):954-962. |
|
|
|
|
|
47.
de Vries YC, Boesveldt S, Kelfkens CS, Posthuma EE, Van den Berg MMGA, de
Kruif JThCM, et al. Taste and smell perception and quality of life during and
after systemic therapy for breast cancer. Breast Cancer Res Treat.
2018;170(1):27-34. |
|